Nephrology

伊藤 辰将

Yoshimasa Ito

基本情報

所属
藤田医科大学 医学部 医学科

ORCID ID
 https://orcid.org/0000-0003-0141-948X
J-GLOBAL ID
201901012614610682
researchmap会員ID
7000029414

論文

 15
  • Tomohiro Mizuno, Fumihiko Nagano, Yoshimasa Ito, Hideki Tatsukawa, Yoshiki Shinoda, Taishu Takeuchi, Kazuo Takahashi, Naotake Tsuboi, Tadashi Nagamatsu, Shuhei Yamada, Shoichi Maruyama, Kiyotaka Hitomi
    Biochemical and biophysical research communications 678 179-185 2023年8月23日  
    Extracellular histones induce endothelial damage, resulting in lung haemorrhage; however, the underlying mechanism remains unclear. Factor XIII, as a Ca2+-dependent cross-linking enzyme in blood, mediates fibrin deposition. As another isozyme, transglutaminase 2 (TG2) has a catalytic activity distributing in most tissues. Herein, we investigated whether TG2 promotes fibrin deposition and mediates the adhesion of platelets to ECs in histone-induced acute lung injury (ALI). We evaluated the lung histology and the adhesion of platelets to endothelial cells (ECs) after injecting histones to wild-type (WT) C57BL/6J and TG2 knockout (TG2-/-) mice, and administered a TG2 inhibitor (NC9) to WT mice. Pulmonary haemorrhage was more severe in TG2-/- mice than that in WT mice. The area of fibrin deposition and the proportion of CD41+CD31+ cells were lower in TG2-/- mice than in WT mice. Pre-treatment of NC9 decreased the area of fibrin deposition and the proportion of CD41+CD31+ cells in WT mice. These results suggest that TG2 prevents from pulmonary haemorrhage in ALI by promoting the adhesion of platelets to ECs and the fibrin deposition.
  • 中嶋 和紀, 袴田 知也, 堀 秀生, 伊藤 辰将, 釘田 雅則, 長尾 静子, 湯澤 由紀夫, 坪井 直毅, 高橋 和男
    JSBMS Letters 47(Suppl.) 92-92 2022年8月  
  • 中嶋 和紀, 袴田 知也, 堀 秀生, 伊藤 辰将, 釘田 雅則, 長尾 静子, 湯澤 由紀夫, 坪井 直毅, 高橋 和男
    JSBMS Letters 47(Suppl.) 92-92 2022年8月  
  • Koki Kato, Tomohiro Mizuno, Takenao Koseki, Yoshimasa Ito, Kazuo Takahashi, Naotake Tsuboi, Shigeki Yamada
    Frontiers in Pharmacology 13 2022年3月25日  
    Information on immune checkpoint inhibitor-induced vasculitides is limited, and predictors for this condition have not been identified. Therefore, we have examined the frequency of immune checkpoint inhibitor-induced vasculitides by analyzing the data recorded in the Japanese Adverse Drug Event Report database. Data from April 2004 to March 2020 were extracted, and vasculitides as an immune-related adverse event was defined according to the 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Adverse event signals were recognized as significant when the reporting odds ratio estimates and lower limits of the corresponding 95% confidence intervals exceeded 1. The use of nivolumab showed a significant signal for vasculitides. Furthermore, significant signals of polymyalgia rheumatica were found when the patients were treated with nivolumab, pembrolizumab, and ipilimumab. In addition, the frequencies of nivolumab- and pembrolizumab-induced polymyalgia rheumatica were higher in patients aged ≥70 years and female patients, respectively. Polymyalgia rheumatica was reported in 38 patients treated with nivolumab; 31 (82%) of these were either in recovery or in remission. Further, polymyalgia rheumatica was reported in 17 patients treated with pembrolizumab; 13 (76%) of these were in recovery or remission, while three (18%) were not. Polymyalgia rheumatica was reported in 12 patients treated with ipilimumab; seven (58%) of these were in recovery or remission. Our study highlights that careful monitoring for the symptom of PMR (e.g., bilateral pain in shoulder and pelvic girdles) is required when the patients are aged >70 years and have been treated with nivolumab and when the patients are women and have been treated with pembrolizumab.
  • 坪井 直毅, 横江 優貴, 伊藤 辰将, 丸山 彰一
    腎と透析 91(3) 446-449 2021年9月  

MISC

 9

講演・口頭発表等

 17